Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Palisade Bio Inc (PALI)

Palisade Bio Inc (PALI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,650
  • Shares Outstanding, K 1,514
  • Annual Sales, $ 250 K
  • Annual Income, $ -12,300 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta 1.39
  • Price/Sales 10.90
  • Price/Cash Flow N/A
  • Price/Book 0.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -2.39
  • Number of Estimates 1
  • High Estimate -2.39
  • Low Estimate -2.39
  • Prior Year -3.75
  • Growth Rate Est. (year over year) +36.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3800 +26.81%
on 12/11/24
3.3000 -46.97%
on 12/12/24
-0.6900 (-28.28%)
since 11/20/24
3-Month
1.3800 +26.81%
on 12/11/24
4.3200 -59.49%
on 10/21/24
-2.0100 (-53.46%)
since 09/20/24
52-Week
1.3800 +26.81%
on 12/11/24
22.3500 -92.17%
on 01/29/24
-6.9800 (-79.95%)
since 12/20/23

Most Recent Stories

More News
Palisade Bio, Inc. Appoints Brian G. Feagan, MD, to Clinical Advisory Board

Palisade Bio appoints Dr. Brian G. Feagan to its Clinical Advisory Board to enhance its autoimmune therapeutic development.Quiver AI SummaryPalisade Bio, Inc. has announced the appointment of Dr. Brian...

PALI : 1.7500 (-2.78%)
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

PALI : 1.7500 (-2.78%)
Palisade Bio, Inc. Closes $5 Million Underwritten Public Offering to Support Clinical Trial and R&D Efforts

Palisade Bio closed a $5 million public offering to fund clinical trials and research for autoimmune and inflammatory diseases.Quiver AI SummaryPalisade Bio, Inc. has successfully closed an underwritten...

PALI : 1.7500 (-2.78%)
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

PALI : 1.7500 (-2.78%)
Palisade Bio, Inc. Announces Pricing of $5 Million Underwritten Public Offering

Palisade Bio announces a $5 million public offering to fund its clinical trials and research efforts.Quiver AI SummaryPalisade Bio, Inc. has announced a public offering of approximately $5 million to develop...

PALI : 1.7500 (-2.78%)
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

PALI : 1.7500 (-2.78%)
Palisade Bio Reports No Adverse Events in Phase 1 Study of PALI-2108 for Ulcerative Colitis

Palisade Bio reports no adverse events in initial dosing cohorts of PALI-2108 for ulcerative colitis, advancing clinical trials.Quiver AI SummaryPalisade Bio, Inc. announced preliminary results from the...

PALI : 1.7500 (-2.78%)
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

PALI : 1.7500 (-2.78%)
Palisade Bio Presents Promising Preclinical Data for PALI-2108 at 8th Annual Antifibrotic Drug Development Summit, Targeting Fibrostenotic Crohn's Disease

Palisade Bio announced promising preclinical results for PALI-2108, targeting fibrotic pathways in Crohn's disease, with enhanced safety profiles.Quiver AI SummaryPalisade Bio has announced promising preclinical...

PALI : 1.7500 (-2.78%)
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

PALI : 1.7500 (-2.78%)

Business Summary

Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 1.9333
2nd Resistance Point 1.8967
1st Resistance Point 1.8233
Last Price 1.7500
1st Support Level 1.7133
2nd Support Level 1.6767
3rd Support Level 1.6033

See More

52-Week High 22.3500
Fibonacci 61.8% 14.3395
Fibonacci 50% 11.8650
Fibonacci 38.2% 9.3905
Last Price 1.7500
52-Week Low 1.3800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar